Applied DNA Sciences Inc (APDN): Forecast Levels Chart
Steady cash flow from the manufacturing of laboratory components allows Applied DNA Sciences (APDN) to cover capital expenditures, with the metric standing at 1125.01. The business relies on linear DNA synthesis for medicine and logistics control, which mitigates narrow specialization risks. This chart demonstrates the asset's market dynamics. Process efficiency is enhanced through automated molecular tagging, eliminating the need for manual control.
%20Analyst%20Consensus%20Forecast&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_APDN_-_Applied-DNA-Sciences_-_Analyst-Consensus-Forecast "APDN - Applied DNA Sciences Broker Consensus Forecast over the range 07/04/2022 - 10/07/2025 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Applied DNA (APDN)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- balance sheet net asset value indicators:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Applied DNA Sciences|APDN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Applied DNA Corp|APDN - Company Aggregate Debts|Debts to Book Capitalization Applied DNA|APDN - Company Long-Term Debts|Company Short-Term Debts Applied DNA Sciences|Critical Liquidity Ratio adnas.com
- net income and valuation multiples indicators:
APDN - Company Net Income|Forward Earnings Applied DNA Sciences|APDN - Price to Earnings Ratio|Future Price to Earnings Applied DNA Sciences Inc|APDN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Applied DNA|APDN - Operating profit EBITDA|Net earnings per one share for the last twelve months Applied DNA Sciences|APDN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months adnas.com|APDN - Net earnings per share growth this year|Expected earnings per share trend next year Applied DNA Sciences
General company analysis:APDN adnas.com
Applied DNA Sciences monetizes innovations in DNA tagging and pharmaceutical diagnostics, leveraging management's deep expertise in brand protection. The trend in analysts' estimated price targets for the stock digitizes market expectations, allowing investors to assess capital risks during mass rating revisions through stress testing and avoid panic selling during periods of volatility.
Competing companies
Analyst Consensus Forecast tempus.com (TEM)|Price Target Chart Qiagen QGEN|IONS (Ionis Pharmaceuticals, Inc.) - Forecast Levels Chart|Repligen Corp. - Analyst Consensus Forecast|RNA (Avidity Corp) - Broker Consensus Forecast|CRISPR Therapeutics AG (CRSP) - Price Target Chart|Broker Consensus Forecast WGS|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|Stoke Therapeutics, Inc. - Analyst Consensus Forecast|BLFS - Analyst Consensus Forecast|Wave Life Sciences Corp (WVE) - Price Target Chart|Forecast Levels Chart MAZE (Maze Therapeutics Corp)|Price Target Chart Sionna Therapeutics Inc|primemedicine.com - Forecast Levels Chart|Price Target Chart Taysha Gene Therapies, Inc. (TSHA)|Price Target Chart QURE (uniQure NV)|Analyst Consensus Forecast MGTX (MeiraGTx PLC)|Analyst Median Target REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Analyst Consensus Forecast|Average Forecast Price ocugen.com|PACB: Analyst Consensus Forecast|Broker Consensus Forecast BNTC|Consensus Target DSGN|RCKT: Fair Value Consensus|Analyst Consensus Forecast FDMT|lexeotx.com - Broker Consensus Forecast|Price Target Chart Korro Bio KRRO|EDIT: Broker Consensus Forecast|Silence Therapeutics Inc. - Analyst Consensus Forecast|PRQR - Analyst Consensus Forecast|CDXS (codexis.com) - Consensus Target|sangamo.com - Fair Value Consensus|Price Target Chart Nautilus Biotechnology, Inc.|Metagenomi Inc. (MGX) - Analyst Median Target|Analyst Consensus Forecast DTIL|Consensus Target generationbio.com GBIO|Analyst Consensus Forecast BOLD (Boundless Bio, Inc.)|Analyst Median Target Exicure Inc. (XCUR)|Celsion Corporation - Analyst Consensus Forecast|Average Forecast Price Phio Pharmaceuticals|mustangbio.com (MBIO) - Price Target Chart|Broker Consensus Forecast RNAZ|BNGO (Bionano Genomics Inc.) - Analyst Consensus Forecast|Consensus Target bluebirdbio.com (BLUE)|Analyst Consensus Forecast IPA|OMGA - Average Forecast Price|Price Target Chart Singular Genomics Systems Inc OMIC|Analyst Median Target Regulus (RGLS)|Syros Pharmaceuticals - Analyst Consensus Forecast|TBIO - Analyst Consensus Forecast|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|Forecast Levels Chart UBX (Unity Biotechnology Inc.)
